The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AMLX | +281.2% | N/A | N/A | -23% |
| S&P | +20.12% | +68.19% | +10.95% | +42% |
Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the provision of disease-modifying solutions for neurodegenerative diseases. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
A Co-CEO of a leading neurotherapeutics developer reported significant insider selling amid a year of standout stock performance. But the sale is not what it seems.
Amylyx Stock is up a staggering 166% over the past year, and this biotech-focused hedge fund is still doubling down.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 100.0% |
| Gross Profit | -$108.00K | 86.9% |
| Gross Margin | -147.60% | 0.0% |
| Market Cap | $1.33B | 412.0% |
| Market Cap / Employee | $9.75M | 0.0% |
| Employees | 136 | 10.6% |
| Net Income | -$32,999.00K | 12.1% |
| EBITDA | -$36,497.00K | 9.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $226.65M | 192.9% |
| Accounts Receivable | $88.00K | -80.3% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $4.70M | 914.7% |
| Short Term Debt | $1.26M | -17.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -54.85% | 30.0% |
| Return On Invested Capital | -190.76% | -136.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$27,989.00K | 52.6% |
| Operating Free Cash Flow | -$27,903.00K | 52.7% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.47 | 2.83 | 7.22 | 3.99 | 202.44% |
| Price to Sales | 0.48 | 0.43 | 1.12 | 2.97 | - |
| Price to Tangible Book Value | 1.47 | 2.83 | 7.22 | 3.99 | 202.44% |
| Price to Free Cash Flow TTM | 12.48 | - | |||
| Enterprise Value to EBITDA | -2.67 | -9.28 | -25.91 | -27.83 | 1229.73% |
| Free Cash Flow Yield | 8.0% | - | |||
| Return on Equity | -83.2% | -87.4% | -56.5% | -61.6% | -38.95% |
| Total Debt | $1.38M | $5.96M | $5.94M | $5.96M | 200.71% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
